1. Home
  2. SKYH vs CINGW Comparison

SKYH vs CINGW Comparison

Compare SKYH & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYH
  • CINGW
  • Stock Information
  • Founded
  • SKYH 2017
  • CINGW N/A
  • Country
  • SKYH United States
  • CINGW United States
  • Employees
  • SKYH N/A
  • CINGW 13
  • Industry
  • SKYH Military/Government/Technical
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • SKYH Industrials
  • CINGW Health Care
  • Exchange
  • SKYH Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • SKYH N/A
  • CINGW N/A
  • IPO Year
  • SKYH N/A
  • CINGW 2021
  • Fundamental
  • Price
  • SKYH $11.35
  • CINGW $0.04
  • Analyst Decision
  • SKYH Buy
  • CINGW
  • Analyst Count
  • SKYH 1
  • CINGW 0
  • Target Price
  • SKYH $16.00
  • CINGW N/A
  • AVG Volume (30 Days)
  • SKYH 267.0K
  • CINGW N/A
  • Earning Date
  • SKYH 05-13-2025
  • CINGW N/A
  • Dividend Yield
  • SKYH N/A
  • CINGW N/A
  • EPS Growth
  • SKYH N/A
  • CINGW N/A
  • EPS
  • SKYH N/A
  • CINGW N/A
  • Revenue
  • SKYH $14,761,000.00
  • CINGW N/A
  • Revenue This Year
  • SKYH $114.21
  • CINGW N/A
  • Revenue Next Year
  • SKYH $77.83
  • CINGW N/A
  • P/E Ratio
  • SKYH N/A
  • CINGW N/A
  • Revenue Growth
  • SKYH 94.86
  • CINGW N/A
  • 52 Week Low
  • SKYH $8.26
  • CINGW N/A
  • 52 Week High
  • SKYH $14.52
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • SKYH 48.13
  • CINGW N/A
  • Support Level
  • SKYH $10.95
  • CINGW N/A
  • Resistance Level
  • SKYH $11.91
  • CINGW N/A
  • Average True Range (ATR)
  • SKYH 0.77
  • CINGW 0.00
  • MACD
  • SKYH -0.13
  • CINGW 0.00
  • Stochastic Oscillator
  • SKYH 30.74
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: